en · de · es · fr · pt
glossary-desk.peptides7501.com › News › Background And Receptor Pharmacology — Practical Notes

Background And Receptor Pharmacology — Practical Notes

By Editorial Desk · published 2025-08-26 · last reviewed 2025-09-17 · News

reference standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Related pages on this site

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Background from the literature

The Phoenicians also made a deep blue-coloured dye, sometimes referred to as royal blue or hyacinth purple, which was made from a closely related species of marine snail. The Phoenicians established an ancillary production facility on the Iles Purpuraires at Mogador, in Morocco. The sea snail harvested at this western Moroccan dye production facility was Hexaplex trunculus, also known by the older name Murex trunculus. This second species of dye murex is found today on the Mediterranean and Atlantic coasts of Europe and Africa (Spain, Portugal, Morocco).

Trans fats occur in meat and dairy products from ruminants. For example, butter contains about 3% trans fat by weight. These naturally occurring trans fats include conjugated linoleic acid (CLA) and vaccenic acid (trans-11 18:1). They arise from the action of bacteria in the rumen. Polyunsaturated fats are toxic to the rumen-based bacteria, which detoxify the fats by changing some cis-double bonds to trans-double bonds. In contrast to industrially produced trans fats, this bacterial process produces only a few specific isomers. Conjugated trans fatty acids such as CLA are exempt from counting as trans fat in the US. The Codex Alimentarius includes an analogous exclusion. As industrial sources of trans fats are eliminated, increased attention focuses on ruminant derived trans fats. Not all ruminant-derived trans fats are innocuous like vaccenic acid and its metabolite rumenic acid (cis-9-trans-11 CLA / 18:2). In particular, trans-10 18:1 is not turned into a conjugated linoleic acid by humans. It appears to have health consequences comparable to trans fats of industrial origin.

=== 23 July === General Al-Taj Youssef Aboukadair, a senior RSF commander also known as Folgank, was killed by an SAF drone strike in Abu Zabad that also killed two other RSF commanders. At least 32 people were killed in an RSF attack on the village of Brima Rashid in West Kordofan.

=== Cancer === Angiogenesis is essential for the supply of oxygen and nutrients to nourish the growing tumor. CCN1 is a powerful angiogenic inducer in vivo, and it can also promote cancer cell proliferation, invasion, survival, epithelial–mesenchymal transition, and metastasis. Accordingly, forced overexpression of CCN1 enhanced tumor growth in xenografts of breast cancer cells, prostate cancer cells, ovarian carcinoma cells, and squamous carcinoma cells. Clinically, CCN1 expression correlates with the tumor stage, tumor size, lymph node positivity, and poor prognosis in several cancers, including breast cancer, prostate cancer, glioma, gastric adenocarcinoma, and squamous cell carcinoma. However, CCN1 can also induce apoptosis and cellular senescence, two well-established mechanisms of tumor suppression Thus, whereas CCN1 can promote the proliferation of prostate cancer cells, it can also exacerbate apoptosis of these cells in the presence of the immune surveillance molecule TRAIL. CCN1 has an inhibitory effect on some cancers, and suppresses tumor growth of non-small-cell lung cancer (NSCLC) cells, endometrial adenocarcinoma cells, and in melanoma cells.

Sources: en.wikipedia.org

Further detail

Nike, Inc announces it will sell "limited quantities" of a replica goalkeeper shirt worn by England goalkeeper Mary Earps during the 2023 Women's World Cup after around 150,000 people signed an online petition calling for them to be made available. A police officer is taken to hospital with critical injuries after being hit by a train while trying to help a distressed man on the railway track in Nottinghamshire. 25 August – Hartwig Fischer announces he will step down as director of the British Museum after treasures were stolen from the London institution. 26 August – Two people are killed after driving a car into a flooded road in the Mossley Hill area of Liverpool. 27 August – The Metropolitan Police launch an investigation into a possible data breach involving details about thousands of their officers after "unauthorised access" was gained to the system of one of its suppliers. 29 August – Nottinghamshire Police officer Sgt Graham Saville, 46, who was struck by a train while trying to help a distressed man on the railway track, dies in hospital from injuries sustained in the incident. London's Ultra Low Emission Zone is expanded to include the whole of Greater London. 30 August – England's Autumn 2023 flu vaccination and COVID-19 booster programme is brought forward by a month, from October to September, as scientists from the UK Health Security Agency monitor the BA.2.86 variant. Although it is not a variant of concern, it is being monitored due to its high number of mutations.

== Coevolution == Coevolution is the long-term outcome of the algae-bacteria interaction. Algae and bacteria interact through mutualism, competition, and antagonistic interactions. Bacteria have evolved mechanisms to utilize algal organic matter or lyse algal cells, while algae have developed defence mechanisms such as resting stages, induced resistance, and chemical signalling responses. This reciprocal adaptation is an evolutionary arms race between algae and bacteria.

==== Singles ==== "Moth/Lake" (2015, Boomkat Editions) "Flora's Theme" (2016, Williams Street Records) "Final Exam" with Kelela and Adrian Piper (2016, The Vinyl Factory) "Solilunita" (2018, Break World Records)

== See also == Drug design Drug metabolism Microbial biodegradation Biodegradation Bioremediation Antioxidant SPORCalc, an example process for exploring xenobiotic and drug metabolism databases Archived 2009-03-18 at the Wayback Machine

=== Subtilisin-like === Subtilisin is a serine protease in prokaryotes. Subtilisin is evolutionarily unrelated to the chymotrypsin-clan, but shares the same catalytic mechanism utilising a catalytic triad, to create a nucleophilic serine. This is the classic example used to illustrate convergent evolution, since the same mechanism evolved twice independently during evolution.

Sources: en.wikipedia.org

Background from the literature

While slavery had technically been banned by colonial France in French West Africa (including Mauritania) already in 1905, this had been a purely nominal ban. The 1981 ban on slavery was not enforced in practice, as legal mechanisms to prosecute those who used slaves were not implemented until 2007.

=== Catholic === American Order of United Catholics - Founded in January 1896 in New York City by Catholics who wished to counter the influence of the American Protective Association. It was "expected of the founders" that they would demand candidates for office who disapproved of the APA or other organizations that sought to discriminate against Catholics. A Supreme Council was organized on March 7, 1896, and the Order was organized "upon the usual secret society lines". They issued a circular that proclaimed that the Church did not oppose secret societies, except those that were oathbound. Catholic Aid Association - Founded in 1878 by German Catholics in Minnesota. The order began with 464 members from 10 parishes and was called the Deutsche Römisch-Katholische Unterstützungs-Gesellschaft von Minnesota; adopted its present name in 1923. Had 58,722 members in 1965, and approximately 78,000 in 1979. Headquarters in St. Paul, Minnesota. Local groups are called "subordinate Councils", of which there were 240 in 1979. Annual convention called the "Grand Council". Has rituals for initiation, installation of officers, and other purposes. Open to Roman Catholics 16-65 who are not a member of a secret society condemned by the Church. Sponsors matching grants program for Catholic elementary schools and religious education programs. Also, a College Tuition Scholarship Program has helped 800 CAA members receive degrees. Also sponsors banquets, family outings, dances, and youth activities; now Catholic United Financial.

== Further reading == Peter Harper; Lois Reynolds; Tilli Tansey, eds. (2010). Clinical Genetics in Britain: Origins and development. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-85484-127-1. Wikidata Q29581774.

== History == Sigma Chemical Company of St. Louis and Aldrich Chemical Company of Milwaukee were both American specialty chemical companies when they merged in August 1975. The company grew throughout the 1980s and 1990s, with significant expansion in facilities, acquisitions and diversification into new market sectors.

Groups such as the Bat Conservation International aim to increase awareness of bats' ecological roles and the environmental threats they face. This group called for Bat Appreciation Week from 24–31 October every year to promote awareness of the ecological importance of bats. In the United Kingdom, all bats are protected under the Wildlife and Countryside Acts, and disturbing a bat or its roost can be punished with a heavy fine. In Sarawak, Malaysia, "all bats" are protected under the Wildlife Protection Ordinance 1998, but species such as the hairless bat (Cheiromeles torquatus) are still eaten by the local communities. Humans have caused the extinction of several species of bat in modern history, the most recent being the Christmas Island pipistrelle (Pipistrellus murrayi), which was declared extinct in 2009. Many people put up bat houses to attract bats. The 1991 University of Florida bat house is the largest occupied artificial roost in the world, with around 450,000–500,000 residents. In Britain, thick-walled and partly underground World War II pillboxes have been converted to make roosts for bats, and purpose-built 'bat bridges' are occasionally built to mitigate damage to habitat from roads or other developments. Cave gates are sometimes installed to limit human entry into caves with sensitive or endangered bat species. The gates are designed not to limit the airflow and thus to maintain the cave's micro-ecosystem. In the United States, 35 of the 47 bat species roost on human-made structures, while 14 of them use bat houses.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

Network